Ophthalmic compositions for treating ocular hypertension

Details for Australian Patent Application No. 2004268012 (hide)

Owner Merck & Co., Inc.

Inventors Shen, Dong-Ming; Doherty, James B.

Agent Spruson & Ferguson

Pub. Number AU-B-2004268012

PCT Pub. Number WO2005/020917

Priority 60/499,628 02.09.03 US

Filing date 27 August 2004

Wipo publication date 10 March 2005

Acceptance publication date 20 November 2008

International Classifications

C07D 307/78 (2006.01) Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom

A61K 31/34 (2006.01) - having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide

Event Publications

9 March 2006 PCT application entered the National Phase

  PCT publication WO2005/020917 Priority application(s): WO2005/020917

20 November 2008 Application Accepted

  Published as AU-B-2004268012

19 March 2009 Standard Patent Sealed

24 March 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004268013-Hydrogel porogens for fabricating biodegradable scaffolds

2004268001-Preventive cancer vaccine based on brother of regulator of imprinted sites molecule (BORIS)